Source: Eur Respir Rev, 29 (155) 190112; 10.1183/16000617.0112-2019
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Michal Shteinberg, Jennifer L. Taylor-Cousar. Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease. Eur Respir Rev, 29 (155) 190112; 10.1183/16000617.0112-2019

Member's Comments

No comment yet.

Related content which might interest you: Early determinants of lung disease in children with cystic fibrosis Source: Virtual Congress 2020 – New frontiers in cystic fibrosis imaging and lung physiology Year: 2020 Clinical characteristics and disease severity of adults with cystic fibrosis with at least one residual function mutation Source: International Congress 2018 – Cystic fibrosis in adults: current research Year: 2018 Impact of lung disease on respiratory impedance in young children with cystic fibrosis Source: Eur Respir J 2015; 46: 1672-1679 Year: 2015 Screening for cystic fibrosis among high risk group patients with chronic lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 340s Year: 2002 Factors affecting progression of lung disease among patients with cystic fibrosis Source: International Congress 2019 – Physiology of cystic fibrosis Year: 2019 Early detection of pulmonary exacerbations in children with cystic fibrosis by electronic home monitoring of symptoms and lung function Source: International Congress 2016 – Cystic fibrosis: monitoring and management Year: 2016 Does lung transplantation affect on the improvement of psychological status in patients with adult cystic fibrosis? Source: International Congress 2018 – Contemporary respiratory care: symptoms, the role of the nurse and the organisation of care Year: 2018 Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation Source: International Congress 2018 – Cystic fibrosis in adults: current research Year: 2018 Early cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 77-87 Year: 2014 Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease Source: Eur Respir J, 57 (2) 2003079; 10.1183/13993003.03079-2020 Year: 2021 The lung clearance index correlates with markers of pulmonary deterioration in patients with cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 Lumacaftor/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis Source: ERJ Open Res, 7 (1) 00203-2020; 10.1183/23120541.00203-2020 Year: 2021 Lung function in children with cystic fibrosis liver disease Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021 Oral contraceptives do not appear to affect cystic fibrosis disease severity Source: Eur Respir J 2013; 41: 67-73 Year: 2013 Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function Source: Eur Respir J, 52 (3) 1702529; 10.1183/13993003.02529-2017 Year: 2018 The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis Source: Breathe, 17 (1) 210013; 10.1183/20734735.0013-2021 Year: 2021 Comparison of progression in lung structure and lung function in children and adolescents with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 714s Year: 2006 Early renal involvement in children with cystic fibrosis. Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research Year: 2018 Short-term effects of physiotherapy on ventilation inhomogeneity in cystic fibrosis patients with moderate to severe lung disease Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013